



**NOTICE OF 10<sup>TH</sup> ANNUAL GENERAL MEETING**

Notice is hereby given that 10<sup>th</sup> Annual General Meeting of the Shareholders of **Takeda Biopharmaceuticals India Private Limited** will be held on **Friday, 12<sup>th</sup> December 2025 at 02:35 P.M. (IST)** through Video Conference (“VC”) or Other Audio-Visual Means (“OAVM”), to transact the following business at a shorter notice.

We would like to inform you that this meeting will be held through video conferencing facility/other audio-visual means in accordance with the applicable provisions of the Companies Act, 2013 read with MCA general circular no. 20/2020, 02/2021, 19/2021, 21/2021, 2/2022, 10/2022, 09/2023, 09/2024 and 03/2025 dated May 05, 2020, January 13, 2021, December 08, 2021, December 14, 2021, May 05, 2022, December 28, 2022, 25<sup>th</sup> September, 2023, 19<sup>th</sup> September, 2024 and 22<sup>nd</sup> September, 2025 respectively.

A Copy of this notice is also being issued to the statutory auditors of the Company in accordance with the Circulars.

You are requested to kindly make it convenient to attend the same.

Takeda Biopharmaceuticals India Private Limited  
(formerly known as Baxalta Bioscience India Private Limited)  
Registered Office : 6th Floor, Tower C, Building No. 8,  
DLF Cyber City, DLF Phase II, Gurgaon, HR 122001 IN  
[www.takeda.com](http://www.takeda.com)  
Tel: +91 (124) 455 9100 / Fax: +91 (124) 455 9109  
CIN : U51909HR2015FTC055144

## ORDINARY BUSINESS

### 1. Adoption of financial statements

To consider and adopt the audited financial statements of the company for the financial year ended 31<sup>st</sup> March, 2025 along with the reports of the Directors' and Auditors thereon.

*To consider and, if thought fit, to pass with or without modification(s) the following resolution as an Ordinary Resolution:*

**“RESOLVED THAT** consent of the Shareholders be and are hereby accorded to adopt the audited financial statements of the company for the financial year ended 31<sup>st</sup> March, 2025 along with the reports of the Directors' and Auditors thereon.”

## NOTES

1. In view of the COVID 19 pandemic, the Ministry of Corporate Affairs ('MCA') has vide its General Circular Nos. 20/2020, 02/2021, 19/2021, 21/2021, 2/2022, 10/2022, 09/2023 and 09/2024 dated May 05, 2020, January 13, 2021, December 08, 2021, December 14, 2021, May 05, 2022, December 28, 2022, 25<sup>th</sup> September, 2023, 19<sup>th</sup> September, 2024, and 22<sup>nd</sup> September, 2025, respectively(collectively referred to as 'Circulars'), has introduced certain measures enabling Companies to convene their Annual General Meetings (AGM/ Meeting) through Video Conferencing (VC) or Other Audio Visual Means (OAVM) and also send notice of the Meeting and other correspondences related thereto, through electronic mode. In compliance with the said requirements of the MCA Circulars, electronic copy of the Notice along with the Annual Report for the financial year ended 31st March, 2025 consisting of financial statements including Board's Report, Auditors' Report and other documents required to be attached therewith (Collectively referred to as Notice) have been sent only to those members whose e- mail ids are registered with the Company.
2. Generally, a member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote on a poll instead of himself and the proxy need not be a member of the Company. Since this AGM is being held through VC / OAVM pursuant to the MCA Circulars, physical attendance of members has been dispensed with. Accordingly, the facility for appointment of proxies by the members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed hereto.



3. Corporate members intending to send their authorized representatives to attend the Meeting are requested to send to the Company a certified copy of the Board Resolution/Authorization letter authorizing their representative to attend and vote on their behalf at the Meeting before the commencement of the meeting.
4. The Register of Directors Shareholding, maintained under Section 170 of the Companies Act, 2013 and the Register of Contracts, maintained under Section 189 of the Companies Act, 2013 will be available for inspection by the Shareholders only in electronic form at the meeting.
5. The meeting shall deem to be held at the Registered office of the Company at 6th Floor, Tower 'C', Building 8, DLF Cyber City, DLF Phase-II, Gurgaon, Haryana-122001, Haryana.
6. Since the AGM will be held through VC/OAVM, the route map to the venue is not annexed to this Notice.

**For and on behalf of the Board of  
Takeda Biopharmaceuticals India Private Limited**

**Gunjan Malhotra  
Company Secretary  
J-153, Patel Nagar 1st  
Ghaziabad 201001 UP**

Place: Gurgaon  
Date: 11.11.2025

Takeda Biopharmaceuticals India Private Limited  
(formerly known as Baxalta Bioscience India Private Limited)  
Registered Office : 6th Floor, Tower C, Building No. 8,  
DLF Cyber City, DLF Phase II, Gurgaon, HR 122001 IN  
[www.takeda.com](http://www.takeda.com)  
Tel: +91 (124) 455 9100 / Fax: +91 (124) 455 9109  
CIN : U51909HR2015FTC055144